bring with them challenges related to both opioid abuse and misuse, often through manipulation of the dosage form. Oxycodone DETERx 
INTRODUCTION
Chronic pain affects an estimated 100 million people in the United States [1] . Opioid analgesics, particularly extended-release (ER)
formulations, are commonly used to treat pain severe enough to require long-term daily, around-the-clock dosing, and for which alternative treatment options are inadequate [2] . Extended-release opioids may provide more consistent control of pain by minimizing fluctuations in plasma concentrations of the drug, thus reducing breakthrough pain [3] .
Extended-release analgesics may also reduce the number of sleep disturbances that result from nighttime breakthrough pain [3] .
Although usually a safe and effective treatment option for patients with chronic pain who are appropriately managed and monitored, ER opioid formulations are associated with high rates of misuse (the use of prescription medications for medical purposes, but not as indicated or prescribed), abuse (the use of drugs for nonmedical purposes, e.g., to get high), and diversion (the channeling of regulated pharmaceuticals to the illicit marketplace, including selling or giving a drug product to any individual for any purpose, even therapeutic) [4] . This is in large part because oral ER opioids may carry a large opioid load [5] . Abusers often manipulate (e.g., cut, crush, or dissolve) ER formulations to more rapidly release most, if not all, of the active drug, with the goal of achieving a more rapid drug high [5] . Further, unintentional misuse can occur when patients or their caregivers manipulate ER formulations for any number of reasons, including to reduce the dose or make the medication easier to swallow.
Manipulation of most ER opioid formulations, regardless of intent, can result in greater exposure to the drug than intended, which can lead to adverse consequences or even death [6] [7] [8] [9] [10] .
An additional challenge to healthcare providers is managing chronic pain in patients who have difficulty swallowing. There are an estimated 11 million people in the United States who experience chronic pain with dysphagia [11] . Although ER formulations offer many benefits in treating chronic pain, there are limited alternative dosing options for patients who have difficulty swallowing. Currently available alternative modes of administration (e.g., rectal or transmucosal/buccal) for treating chronic pain are limited by such factors as variable absorption rates [11, 12] , ceiling doses, and boxed warnings provided in package inserts advising against crushing or chewing pellet formulations when sprinkled onto food [6, 7, 13] .
Treatment of pain in this patient population is further complicated because newer analgesics that are abuse deterrent may be formulated as hard, monolithic tablets and with agents that gel when exposed to water (e.g., polyethylene oxide), making the exterior of the tablet ''sticky'' when moistened and more difficult to swallow. There have been several reports of currently marketed abuse-deterrent tablet formulations that have become stuck in patients' throats, causing choking, gagging, or regurgitation [8, 10] . Therefore, patients with chronic pain who have difficulty swallowing may manipulate their opioid analgesic to make it easier to swallow. In a survey of more than 1000 patients, 29% reported having difficulty swallowing pills and 10% reported that they sometimes or always manipulate their opioids (e.g., cut, break, crush) to facilitate swallowing [11] . For incapacitated patients, caregivers may manipulate the medication on behalf of the patient. Unfortunately, patients and caregivers are often unaware that this misuse of an ER opioid by manipulation can lead to an increased risk for adverse reactions, overdose, and death [11] .
Although rates of misuse and abuse have stabilized over the past few years, they are still high; in 2014, approximately 4.3 million people aged 12 years and older reported past-month nonmedical use of prescription opioids in the United States [14] , and a comprehensive literature review found that 22-29% of patients misuse opioids [15] . Because of concerns about public health, the US Food and Drug Administration (FDA) considers the development of abuse-deterrent opioids to be a priority [16] . To help guide development of new abuse-deterrent opioid analgesics, the FDA released a final guidance document in 2015 on the evaluation of abuse-deterrent opioids, which outlined four categories needed to comprehensively evaluate prospective abuse-deterrent opioids in the premarket and postmarket contexts [16] . The FDA guidelines included laboratory-based in vitro manipulation and extraction studies (category 1), in vivo pharmacokinetic studies assessing manipulated drugs (category 2), human abuse-potential studies (category 3), and postmarketing studies (category 4) [16] .
Different 
DOSING CONSIDERATIONS AND OPTIONS
Oxycodone DETERx is formulated with oxycodone base, which has a molecular weight 90% that of oxycodone hydrochloride (HCl). Therefore, a 9-mg dose of oxycodone DETERx contains an amount of active drug equivalent to a 10-mg dose of oxycodone HCl. Table 1 shows the available strengths of oxycodone DETERx along with the equivalent amount of oxycodone HCl present in other oxycodone products.
Oxycodone DETERx provides delivery of oxycodone over 12 h, and should be administered twice daily, every 12 h, with food. Because of its lipophilic microsphere design, the peak plasma concentration (C max ) and extent of absorption (area under the curve, AUC) are both lower when oxycodone DETERx is dosed under fasted conditions compared with fed conditions. Therefore, each dose of oxycodone DETERx should be taken with approximately the same amount of food to ensure adequate absorption and consistent plasma concentrations. 
Flexible Dosing/Alternative Administration
In a survey of more than 1000 patients, 10%
reported that they sometimes or always cut, crush, or grind their pain medication; however, (Table 3) . During the titration Fig. 3 Change in the marginal mean (pain score) from randomization baseline to week 12. Pain intensity was rated on a numerical rating scale of 0-10 (0 = ' 'no pain'', 10 = ' 'pain as bad as you can imagine' '). Data are presented as the marginal mean ± standard error. *p\0.0001 (Fig. 2b,  c) . The pharmacokinetic profile of physically manipulated microspheres was bioequivalent to that of intact oxycodone DETERx capsules.
When compared with crushed IR oxycodone, the C max for all oxycodone DETERx treatments was lower and the time to maximum plasma concentration (T max ) was longer, which is consistent with an ER profile [23, 25] .
Insufflation is the second most common form of oxycodone abuse [18] , and is a practice associated with adverse consequences including nasal/palatal necrosis and perforation, overdose, and death [29] . The pharmacokinetic profile of intranasally administered crushed oxycodone DETERx was assessed in nondependent subjects.
Intranasal administration of crushed oxycodone
DETERx did not result in higher peak plasma concentrations than did orally administered oxycodone DETERx, unlike that of intranasal administration of crushed IR oxycodone, which produced as much as twice the oxycodone C max ( intact oxycodone DETERx, chewed oxycodone DETERx, crushed IR oxycodone HCl in water, and placebo. The mean maximum (peak) effect (E max ) for drug liking was significantly lower for chewed and intact oxycodone DETERx than for crushed IR oxycodone (p\0.0001 for both; Fig. 4 ). The differences in ''take drug again'' scores for chewed and intact oxycodone DETERx compared with crushed IR oxycodone were small and not statistically significant.
Intranasal administration is the second most common mode of abuse for oxycodone [18] . The intranasal abuse potential of oxycodone DETERx was assessed in a (category 3) randomized, double-blind, positive-and placebo-controlled crossover study [26] . The four treatments included oxycodone DETERx administered as either an intact oral capsule or a crushed intranasal preparation, IR oxycodone administered intranasally, and placebo. Of the 39 nondependent, nontolerant, recreational opioid abusers (with a history of intranasal abuse) enrolled in the study, 36 subjects completed all four treatment periods. Intranasal administration of crushed oxycodone DETERx was associated with significantly lower mean drug liking (Fig. 4) and ''take drug again'' scores compared with crushed intranasal IR oxycodone (p\0.0001 for both). More than half of the subjects (58%) had a 50% or greater reduction in drug liking with intranasal oxycodone DETERx relative to intranasal IR oxycodone; 92% of subjects had some reduction in drug liking relative to intranasal IR oxycodone (Fig. 5) .
Therefore, data from the pharmacokinetic studies (indicating lower drug exposure of Reducing the propensity of a formulation to ''dose dump'' on manipulation may interrupt the progression of abuse from oral abuse as a gateway to intranasal or other more dangerous routes, which could in turn reduce morbidity and mortality related to opioids [5] . intact, sprinkling onto food, or administered through nasogastric/gastrostomy tubes), so healthcare practitioners can choose the mode of administration that best fits their patients' needs.
As new abuse-deterrent agents come to market, it is important that clinicians review results from both pharmacokinetic and abuse-potential studies to help them evaluate products individually. For example, oxycodone DETERx resists changes to its ER profile when manipulated and administered orally, exhibits a lower nasal abuse potential compared with IR oxycodone, and has physicochemical properties expected to make abuse by injection difficult.
Clinicians
should consider using abuse-deterrent formulations in their practice, but should still recognize that, although they possess properties conferring some level of abuse deterrence, the abuse of these agents is still possible.
In 
